B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 11.8 NOK -5.9% Market Closed
Market Cap: 479.2m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Bergenbio ASA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bergenbio ASA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
B
Bergenbio ASA
OSE:BGBIO
Cash from Financing Activities
kr137.2m
CAGR 3-Years
109%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash from Financing Activities
kr67.6m
CAGR 3-Years
-26%
CAGR 5-Years
14%
CAGR 10-Years
0%
L
Lytix Biopharma AS
OSE:LYTIX
Cash from Financing Activities
-kr943k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Cash from Financing Activities
-kr1.8m
CAGR 3-Years
23%
CAGR 5-Years
10%
CAGR 10-Years
N/A
N
Nykode Therapeutics ASA
OSE:NYKD
Cash from Financing Activities
$43.7m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Cash from Financing Activities
kr168k
CAGR 3-Years
-93%
CAGR 5-Years
-76%
CAGR 10-Years
-40%
No Stocks Found

Bergenbio ASA
Glance View

Market Cap
461.2m NOK
Industry
Biotechnology

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

BGBIO Intrinsic Value
0.2 NOK
Overvaluation 98%
Intrinsic Value
Price
B

See Also

What is Bergenbio ASA's Cash from Financing Activities?
Cash from Financing Activities
137.2m NOK

Based on the financial report for Sep 30, 2024, Bergenbio ASA's Cash from Financing Activities amounts to 137.2m NOK.

What is Bergenbio ASA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
12%

Over the last year, the Cash from Financing Activities growth was -37%. The average annual Cash from Financing Activities growth rates for Bergenbio ASA have been 109% over the past three years , 12% over the past five years .

Back to Top